ITM to Announce Phase 3 COMPETE Trial Post-Hoc Subgroup Analysis in Pancreatic Neuroendocrine Tumors and Host Satellite Symposium at ENETS 2026

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will provide further exploratory and post-hoc subgroup analysis data focusing on ...
Business Wire

Celltrion presents 2-year post-hoc analysis findings for subcutaneous infliximab (CT-P13 SC), highlighting dose escalation as an option for managing loss of response in ...

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion today announced two-year results of subcutaneous infliximab (CT-P13 SC) dose escalation therapy at United European Gastroenterology (UEG) Week 2024 in ...
The American Journal of Managed Care

Post Hoc Analysis Findings Offer Guidance for Anemia Management in Myelofibrosis: Pankit Vachhani, MD

A post hoc analysis of the phase 3b JUMP trial supports the real-world use of ruxolitinib with anemia supportive care to maintain dosing and clinical outcomes in patients with myelofibrosis, offering ...
Nasdaq

CalciMedica Presents New Data From Post Hoc Analysis Of Phase 2 CARDEA Study Of Auxora

(RTTNews) - CalciMedica Inc. (CALC), a clinical-stage biopharmaceutical company, Tuesday said it presented new data based on a post-hoc analysis from the previously completed Phase 2 CARDEA study of ...
Morningstar

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

− Cardiovascular Magnetic Resonance (CMR) and Echocardiographic Analyses Demonstrate that Treatment with Vutrisiran Resulted in Significant Changes on Multiple Functional and Structural Cardiac ...
EurekAlert!

New post-hoc analysis shows patients whose clinicians had access to GeneSight results for depression treatment are more likely to feel better sooner

SALT LAKE CITY, Oct. 30, 2025 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in ...
Medscape

When in Breast Cancer Treatment Are CDK4/6 Inhibitors Best?

Researchers examined whether CDK4/6 inhibitors lead to better overall survival when used as first- or second-line treatment.
Nasdaq

Amicus Therapeutics Publishes Positive Post-Hoc Analysis of Cipaglucosidase Alfa-Atga + Miglustat in Late-Onset Pompe Disease

Amicus Therapeutics has released a post-hoc analysis from the PROPEL study, published in Muscle and Nerve, which evaluated the efficacy of cipaglucosidase alfa-atga combined with miglustat (cipa+mig) ...
The American Journal of Managed Care

Post Hoc Analysis Supports Axatilimab in Heavily Pretreated Patients With Chronic GVHD: Carrie Kitko, MD

The post hoc analysis of the AGAVE-201 trial found that axatilimab demonstrated consistent response rates in patients with chronic graft-vs-host disease (GVHD), regardless of the number or type of ...
Pharmabiz

Partner Therapeutics announces positive data from post hoc analysis of eNRGy trial evaluating treatment beyond progression with zenocutuzumab in patients with advanced NRG1+ NSCLC

Partner Therapeutics announces positive data from post hoc analysis of eNRGy trial evaluating treatment beyond progression with zenocutuzumab in patients with advanced NRG1+ NSCLC Lexington, ...